Feb 4 (Reuters) - Cigna Corp's Express Scripts has settled the U.S. Federal Trade Commission's claims its insulin pricing practices violated antitrust and consumer protection laws, and agreed to ...

The Federal Trade Commission (FTC) has secured a landmark settlement with one of the nation’s largest pharmacy benefit managers (PBMs), Express Scripts, Inc., and its affiliated entities ...

According to Express Scripts, its new pharmacy benefits model, first announced in October 2025, could lower brand name prescription drug costs by as much as 30% and make negotiated discounts available ...

1. FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients. United States Federal Trade Commission. February 4, 2026. Accessed February 5, 2026.

The Federal Trade Commission has announced what it called a "landmark settlement" with Express Scripts over insulin pricing. The settlement resolves a lawsuit alleging that Express Scripts' conduct ...

Express Scripts, a pharmacy benefit manager and subsidiary of Cigna (CI), has reached a settlement with the FTC over accusations that it artificially inflated the prices of insulin drugs, violating ...

The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices. By Rebecca Robbins and Reed Abelson The reporters have ...

Pharmacy benefit managers, which set how drugs are covered by health insurance, have faced a decade of scrutiny from regulators and lawmakers over pricing.